Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
作者信息
Evans W K, Shepherd F A, Blackstein M E, Osoba D, Taylor D
出版信息
Cancer Treat Rep. 1985 Jun;69(6):727-8.
PMID:4016779
Abstract
摘要
相似文献
1
Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Cancer Treat Rep. 1985 Jun;69(6):727-8.
2
Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Cancer Treat Rep. 1982 Oct;66(10):1869-71.
3
Treatment of advanced non-small cell lung cancer with bisantrene.
Cancer Treat Rep. 1983 Jun;67(6):597-8.
4
Phase II trial of bisantrene for advanced hypernephroma.
Cancer Treat Rep. 1982 Aug;66(8):1653-5.
5
Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Cancer Treat Rep. 1985 Feb;69(2):209-10.
6
Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Cancer Treat Rep. 1984 Jun;68(6):927-8.
7
Bisantrene, an active drug in patients with advanced breast cancer.
Cancer Treat Rep. 1984 Feb;68(2):357-60.
8
Phase II trial of bisantrene in advanced colorectal carcinoma.
Cancer Treat Rep. 1983 Mar;67(3):307-8.
9
Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cancer Treat Rep. 1986 Mar;70(3):423-4.
10
Phase II trial of 4'epi-adriamycin for advanced hypernephroma.
Am J Clin Oncol. 1983 Oct;6(5):553-4.
Zotero 插件